stockrow
Saturday 7 November 2026
Export RGNX’s income statement to Excel — free account
REGENXBIO Inc.
RGNX Healthcare Biotechnology
REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024.
- Revenue
- −69.2%
- EPS
- +48.0%
- Free cash flow
- +168.1%
Quarter to September 2026, against a year earlier
7.56
0.18
+2.44%
Follow RGNX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.36 | 5.00 | 3.63 | 3.19 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.20) | (5.77) | (10.17) | (7.90) | |
P/B ratio |
7.23 | 20.84 | 8.82 | 3.32 | |
Price to Tangible BV |
7.23 | 20.84 | 8.82 | 3.32 | |
EV/Sales |
3.04 | 3.36 | 3.05 | 1.60 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.18) | (1.26) | (2.16) | (1.62) | |
EV/FCF |
(4.10) | (1.25) | (2.13) | (1.59) | |
Quick Ratio |
2.17 | 2.26 | 2.57 | 3.84 | |
Current Ratio |
2.38 | 2.62 | 2.86 | 4.74 | |
Net Debt/EBITDA |
4.28 | 1.87 | (3.25) | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.37 | 0.21 | 0.36 | 0.31 | |
Operating CF/Net income |
0.78 | 0.85 | (2.74) | 0.00 | |
Capex/Depreciation |
(0.13) | (0.41) | (0.23) | 0.00 | |
Interest Coverage |
(4.69) | (9.57) | 3.76 | (4.76) | |
Research and Development Expense of Revenue |
196.50% | 896.90% | 51.92% | 665.89% | |
Selling, General and Administrative Expense of Revenue |
73.77% | 333.27% | 20.01% | 224.61% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
27.61% | 134.79% | 8.38% | 0.00% | |
Graham Net Nets |
(0.09) | (0.31) | (0.12) | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(26.11%) | (66.83%) | (31.64%) | (42.69%) | |
Free Cash Flow Yield |
(17.02%) | (53.81%) | (39.46%) | (31.50%) | |
Revenue per Share |
0.59 | 0.12 | 2.05 | 0.14 | |
Operating CF per Share |
(1.01) | (1.45) | (1.18) | 0.00 | |
Capex per Share |
(0.01) | (0.02) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.02) | (1.48) | (1.19) | 0.00 | |
Cash per Share |
4.46 | 2.87 | 2.00 | 3.85 | |
Shareholders Equity per Share |
1.99 | 0.40 | 1.36 | 2.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.99 | 0.40 | 1.36 | 2.27 | |
Free Cash Flow |
(52.80) | (77.42) | (63.00) | 38.42 | |
Working Capital |
163.19 | 115.41 | 153.54 | 253.21 | |
Capital Expenditures |
(0.51) | (1.23) | (0.76) | (0.19) | |
Net Current Asset Value |
(69.02) | (134.30) | (78.70) | 2.89 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.19 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
23.43 | 14.12 | 63.48 | 16.94 | |
Average Payables |
22.08 | 20.13 | 18.60 | 17.87 | |
Average Assets |
459.51 | 416.41 | 483.82 | 495.62 | |
Average Common Equity |
181.19 | 147.64 | 142.72 | 154.75 |
Columns are period end dates · fundamentals updated 6 Nov 2026